Abstract
Background
WHO grade II and III meningiomas are more invasive than grade I malignancies and determine patients’ shorter overall survival. Their tendency to recur after treatment has represented an important therapeutic challenge because of the limited treatment strategies at recurrence. Angiogenesis and mechanistic target of rapamycin (mTOR) activation are two of the main features of higher grade meningiomas, determining invasiveness and tendency to relapse. While these options prove promising, available clinical data on mTOR inhibitors’ efficacy are somewhat limited.
Case study
We report a case of a 25-year-old female patient diagnosed with a right parasagittal occipital anaplastic meningioma (grade III WHO) in 2013. The patient underwent multiple treatments and, in 2019, a further recurrence occurred. The patient reported an mTOR mutation, and it is for this reason that the MTB approved treatment with everolimus and bevacizumab. Therapy was administered in May 2019, and partial response and prolonged disease control was obtained in November 2021, when progression took place. The patient’s death occurred in March 2022.
Conclusions
This case report provides evidence on the efficacy of mTOR inhibitors as a treatment option in recurrent meningiomas. Furthermore, it highlights the importance of performing a molecular analysis as a preliminary step towards targeting the mTOR pathway.
This is a preview of subscription content, log in via an institution to check access.
References
Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, Von Deimling A, Debus J, Combs SE (2012) Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas–clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys 83:859–864
Shao Z, Liu L, Zheng Y, Tu S, Pan Y, Yan S, Wei Q, Shao A, Zhang J (2020) Molecular mechanism and approach in progression of meningioma. Front Oncol 11(10):538845. https://doi.org/10.3389/fonc.2020.538845
Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD et al (2012) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45:285–289
Pinker B, Barciszewska AM (2022) mTOR signaling and potential therapeutic targeting in meningioma. Int J Mol Sci 23(4):1978. https://doi.org/10.3390/ijms23041978
Shih KC, Chowdhary S, Rosenblatt P, Weir AB 3rd, Shepard GC, Williams JT, Shastry M, Burris HA 3rd, Hainsworth JD (2016) A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 129(2):281–288. https://doi.org/10.1007/s11060-016-2172-3
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
None.
Conflict of interest
None.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Villani, V., Tanzilli, A., Vidiri, A. et al. Malignant meningioma mTOR mutated and precision medicine. Neurol Sci 44, 1073–1075 (2023). https://doi.org/10.1007/s10072-022-06575-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-022-06575-x